Compile Data Set for Download or QSAR
Report error Found 226 Enz. Inhib. hit(s) with all data for entry = 12583
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712286(US20250011311, Example 103)
Affinity DataIC50: 26nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712204(US20250011311, Example 21)
Affinity DataIC50: 32nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712216(US20250011311, Example 33)
Affinity DataIC50: 34nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712187(US20250011311, Example 4)
Affinity DataIC50: 36nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712186(US20250011311, Example 3)
Affinity DataIC50: 36nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712196(US20250011311, Example 13)
Affinity DataIC50: 40nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712189(US20250011311, Example 6)
Affinity DataIC50: 41nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712275(US20250011311, Example 92)
Affinity DataIC50: 41nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712307((5-(2-Bromo-3,4,6-trifluoro-5-hydroxyphenyl)-1,2,4...)
Affinity DataIC50: 42nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712303(US20250011311, Example 120)
Affinity DataIC50: 44nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712251((4-((5-Methoxypyridin-2- yl)oxy)piperidin-1-yl)(5-...)
Affinity DataIC50: 44nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712245((4-Phenyl-3,6- dihydropyridin- 1(2H)-yl)(5-(2,4,5-...)
Affinity DataIC50: 46nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712297(US20250011311, Example 114)
Affinity DataIC50: 46nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712292(US20250011311, Example 109)
Affinity DataIC50: 46nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712191(US20250011311, Example 8)
Affinity DataIC50: 47nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712279(US20250011311, Example 96)
Affinity DataIC50: 47nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712277(US20250011311, Example 94)
Affinity DataIC50: 48nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712247((3,4- Dihydroisoquinolin-2(1H)- yl)(5-(2,4,5-trifl...)
Affinity DataIC50: 48nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712244((4-(3-Methoxyphenyl) piperazin-1-yl)(5- (2,4,5-tri...)
Affinity DataIC50: 50nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712284(US20250011311, Example 101)
Affinity DataIC50: 50nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712285(US20250011311, Example 102)
Affinity DataIC50: 52nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712278(US20250011311, Example 95)
Affinity DataIC50: 53nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712287(US20250011311, Example 104)
Affinity DataIC50: 57nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712220(((3R,5S)-3,5- Dimethylpiperidin-1- yl)(5-(2,4,5-tr...)
Affinity DataIC50: 57nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712213(US20250011311, Example 30)
Affinity DataIC50: 61nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712255((4-(Benzo[d]oxazol-2- yl)piperazin-1-yl)(5-(2,4,5-...)
Affinity DataIC50: 62nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712265(2-(4-(5-(2,4,5-Trifluoro-3- hydroxyphenyl)-1,2,4- ...)
Affinity DataIC50: 62nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712281(US20250011311, Example 98)
Affinity DataIC50: 63nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712276(US20250011311, Example 93)
Affinity DataIC50: 63nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712203(US20250011311, Example 20)
Affinity DataIC50: 63nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712254(N-((5,6-Dimethyl-1H- benzo[d]imidazol-2-yl) methyl...)
Affinity DataIC50: 68nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712194(US20250011311, Example 11)
Affinity DataIC50: 69nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712260((1-Phenyl-3- azabicyclo[3.1.0]hexan-3- yl)(5-(2,4,...)
Affinity DataIC50: 75nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712185(US20250011311, Example 2)
Affinity DataIC50: 75nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712306((6-Methyl-5-oxa-8-azaspiro[3.5]nonan-8-yl)(5-(2,4,...)
Affinity DataIC50: 77nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712250((4-(3-Chloro-5-(2-methyl-2H- tetrazol-5-yl)pyridin...)
Affinity DataIC50: 79nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712201(US20250011311, Example 18)
Affinity DataIC50: 80nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712291(US20250011311, Example 108)
Affinity DataIC50: 80nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712224((Hexahydrocyclopenta [b][1,4] oxazin-4(4aH)-yl) (5...)
Affinity DataIC50: 82nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712190(US20250011311, Example 7)
Affinity DataIC50: 83nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712305(rac-((2R,6S)-2-isopropyl-6-methylmorpholino)(5-(2,...)
Affinity DataIC50: 85nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712240((4-(3-(4- Fluorophenoxy) propyl)piperazin- 1-yl)(5...)
Affinity DataIC50: 88nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712256(N-Methyl-N-((5-methyl- 1H-benzo[d]imidazol- 2-yl)m...)
Affinity DataIC50: 88nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712257((3-(4-Fluorophenyl)azetidin- 1-yl)(5-(2,4,5- trifl...)
Affinity DataIC50: 89nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712294(US20250011311, Example 111)
Affinity DataIC50: 93nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712188(US20250011311, Example 5)
Affinity DataIC50: 93nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712264((4-Phenylpiperazin-1-yl)(5- (2,4,5-trifluoro-3- hy...)
Affinity DataIC50: 95nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712269(US20250011311, Example 86)
Affinity DataIC50: 102nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712266(4-(4-(5-(2,4,5-Trifluoro-3- hydroxyphenyl)-1,2,4- ...)
Affinity DataIC50: 102nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Astrazeneca

US Patent
LigandPNGBDBM712241((4-(Pyridin-2-yl) piperazin-1-yl)(5- (2,4,5-triflu...)
Affinity DataIC50: 103nMAssay Description:Final assay conditions were 80 nM of 17bHSD13, 0.5 mM of NAD, 20 μM Estradiol and various concentrations of compound in buffer (5 mM EDTA (TEKNOVA E0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/22/2025
Entry Details
US Patent

Displayed 1 to 50 (of 226 total ) | Next | Last >>
Jump to: